Australia’s Neuren Pharmaceuticals (ASX: NEU) has announced top-line results from its Phase II trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS).
Statistically-significant improvement from baseline was observed by both clinicians and caregivers from treatment, across all four efficacy measures that were specifically designed to assess the core characteristics of PTHS.
"This underserved community has such urgent unmet need"There are no approved treatments for PTHS, despite its severely debilitating impact on the lives of patients, as well as their parents and siblings.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze